Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > market CRAZYNESS

<< Previous

Bullboard Posts

Next >>

Comment by bluemoons20on Jan 27, 2023 9:57am

100 Views

Post# 35249944

RE:RE:RE:RE:RE:RE:market CRAZYNESS

Good thoughts. However , if there is something good coming , why raise more money since they just raised some and the arbitration result is very near. If its good news , insiders could delay salary for a few months. Besdies , what do you need operating capital for except salaries. You ask yourself the question , Why pay people if nothing is going on??

I have been in here for quite a number of years and it seems to just keep getting worse.
Soon we will be looking at a share consolidation!!!

I hope we get some good news soon!!

GLTA

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing